Breaking News, Collaborations & Alliances

Nanna Therapeutics Taps Ubiquigent for Its DUB Focused Drug Discovery Platform

Will support the development of novel therapeutics for human disease targets selected by Nanna.

Author Image

By: Charlie Sternberg

Associate Editor

Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, has announced an agreement with Nanna Therapeutics, under which Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.   DUB enzymes regulate ubiquitination in the ubiquitin-proteasome syst...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters